There is strong clinical evidence that PARPi delays disease progression in BRCA germline pathogenic variant carriers with metastatic HER2-negative BC who have previously been treated with CT in the neoadjuvant, adjuvant, or metastatic setting. This evidence concerns the gene ERBB2 and breast cancer.